Scotland Recommends Interim Funding For Regeneron/Sanofi’s Libtayo
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
You may also be interested in...
Novartis’s Luxturna and Kyowa Kirin’s Crysvita are the first drugs to be evaluated through Scotland’s new ultra-orphan process.
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.